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Abstract
Background: Host defense against invading pathogens is triggered by various receptors including toll-like receptors (TLRs).
Activation of TLRs is a pivotal step in the initiation of innate, inflammatory, and antimicrobial defense mechanisms. Human
b-defensin 2 (HBD-2) is a cationic antimicrobial peptide secreted upon Gram-negative bacterial perturbation in many cells.
Stimulation of various TLRs has been shown to induce HBD-2 in oral keratinocytes, yet the underlying cellular mechanisms
of this induction are poorly understood.
Principal Findings: Here we demonstrate that HBD-2 induction is mediated by the Sphingosine kinase-1 (Sphk-1) and
augmented by the inhibition of Glycogen Synthase Kinase-3b (GSK-3b) via the Phosphoinositide 3-kinase (PI3K) dependent
pathway. HBD-2 secretion was dose dependently inhibited by a pharmacological inhibitor of Sphk-1. Interestingly, inhibition
of GSK-3b by SB 216763 or by RNA interference, augmented HBD-2 induction. Overexpression of Sphk-1 with concomitant
inhibition of GSK-3b enhanced the induction of b-defensin-2 in oral keratinocytes. Ectopic expression of constitutively active
GSK-3b (S9A) abrogated HBD-2 whereas kinase inactive GSK-3b (R85A) induced higher amounts of HBD-2.
Conclusions/Significance: These data implicate Sphk-1 in HBD-2 regulation in oral keratinocytes which also involves the
activation of PI3K, AKT, GSK-3b and ERK 1/2. Thus we reveal the intricate relationship and pathways of toll-signaling
molecules regulating HBD-2 which may have therapeutic potential.
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Introduction
Infection caused by sepsis is one of the leading causes of death in
the United States [1,2,3]. Controlling inflammation from bacterial
sepsis remains a challenge and antimicrobial peptides may have
therapeutic utility [4]. Antimicrobial peptides, predominantly
produced by epithelial linings, have shown broad spectrum
activity against bacteria, fungi, viruses and parasites [5]. Defensins
are potent cationic antimicrobial peptides present in mammals and
insects [6,7,8,9] consisting of two classes based on their structural
characteristics, namely, a-defensins and b-defensins. Human a-
defensins are found in granules of phagocytes and Paneth cells,
whereas human b-defensins 2 (HBD-2) are highly expressed by
epithelial cells [10,11,12]. Epithelial cells are a first line of defense
against bacterial attack and thus understanding defensin induction
mechanisms in these cells is crucial.
Sphingosine kinase-1 (Sphk-1) isan important intracellular enzyme
that catalyzes a novel lipid messenger Sphingosine-1-phosphate (S1P)
which regulates cellular proliferation and survival and histone
acetylation [13,14,15] and activation implicated in cardio protection
[16,17,18]. S1P is also a ligand for EDG1 (endothelial differentiation
gene 1) receptor that regulates diverse cellular function [19]. Sphk-1
has been shown to regulate the MAPK signaling pathway and
activates NF-kb [20], and is highly expressed in various types of
cancers [14] presumably associated with tumor angiogenesis.
Recently, S1P has been shown to induce antimicrobial activity with
both in vitro and in vivo animal infection models of Mycobacterium
tuberculosis [21,22,23]. In the present investigation, we identified the
involvement of Sphk-1 in the induction of b-defensin 2 in human
gingival epithelial cells (HGECs) and also found that the inhibition of
kinase glycogen synthase kinase-3b (GSK3-b)a u g m e n t sH B D - 2 ,a l l
of which may have therapeutic application.
Methods
Ethics statement
Gingival tissue biopsies were obtained with written informed
consent from periodontally healthy patients undergoing crown-
lengthening procedures at the University of Louisville’s School of
Dentistry with an Institutional Review Board approval. The
gingiva was treated with 0.025% trypsin and 0.01% ethylenedi-
aminetetraacetic acid overnight at 4uC and HGECs were isolated
as previously described [24].
Reagents
The cell culture medium was purchased from Invitrogen, CA.
toll-like receptor (TLR) agonists namely, heat inactivated P.
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(Pam2CGDPKHPKSF), Pam3CSK4, P. gingivalis LPS, E. Coli
LPS, ssRNA, Poly I:C, ODN 2006, Imiquimod, Flagellin were
purchased from Invivogen, CA. Cell culture tested IL-1a, IL-1b
and TNF-a cytokines were purchased from R&D Systems, S1P
from Biomol International, PA. Sphk-1 (2-(p-Hydroxyanilino)-4-(p-
chlorophenyl) thiazole) is a specific inhibitor for Sphk-1 that blocks
the production of S1P), Wortmannin, U0126, LY 294002 and Akt
inhibitors were purchased from EMD chemicals, NJ and SB
216763 was purchased from Tocris Bioscience, MO. Pre-validated
siRNA specific to siSphk-1, siGSK-3b,control siRNA and
transfection reagent siPORT NeoFX were purchased from
Ambion, CA. Fugene 6 was purchased from Roche, IN. TransAM
NF-kB p65 kit was purchased from Active Motif, CA and the
ELISA kit for S1P was procured from Echelon Biosciences, UT,
HBD-2 ELISA kit was from Peprotech, NJ and IL-6, IL-1b and
TNF-a were from BD biosciences, CA. The antibodies phospho-
Glycogen synthase (Ser641), phospho-p44/42 MAPK (ERK 1/2)
and b-actin were purchased from Cell Signaling Technology, MA
and phospho-Sphk-1 (ser225) was from ECM biosciences, KY.
Cell culture and Challenge assays
HGECs were isolated and cultured as previously described
[24,25]. Briefly, when the cells were restored from frozen, they
were subcultured and when reached confluence, they were
pretreated for 2 h with 0.1 mM, 0.2 mM, 0.3 mM, 0.5 mM,
0.8 mM, 1.0 mM, 2.0 mM, 5.0 mM of Sphk-1 inhibitor and then
challenged with FSL-1 (1 mg/ml) for 24 h. For TLR activation,
heat inactivated P. gingivalis (MOI:100), FSL-1 (1 mg/ml),
Pam3CSK4 (0.5 mg/ml), P. gingivalis LPS (1 mg/ml), E. Coli LPS
(1 mg/ml), ssRNA (0.1 mg/ml), Poly I:C (5 mg/ml) ODN (0.5 mg/
ml), Imiquimod (0.1 mg/ml), Flagellin (0.25 mg/mL), for IL-1R
and TNF, IL-1a (2.5 ng/ml), IL-1b (2.5 ng/ml) and TNF-a
(2.5 ng/ml) and S1P (100 nM) either in the presence or absence of
Sphk-1 inhibition (2 mM). The challenge assay was performed for
24 h and culture supernatant was then collected. The secreted
HBD-2 and cellular S1P was measured by ELISA. and NF-kB p65
was measured using TransAM NF-kB p65 kit in cells challenged
with FSL-1 for 12 h after inhibiting Sphk-1 or GSK3.
Real-time PCR
Total RNA was extracted from cultured cells by using TRIzol
reagent (Invitrogen, Carlsbad, CA). The isolated total RNA
samples were used to perform first strand cDNA synthesis (Applied
Biosystems, Foster City, CA). Real-time PCR was performed by
using 50 ng of cDNA with Sphk-1 (Assay ID: Hs00184211_m1),
Sphk-2 (Hs00219999_m1) and GAPDH (Assay ID: 4333764F) as
endogenous control as primers and probes on an ABI 7500 system
(Applied Biosystems) in the presence of TaqMan DNA polymerase
as previously described [26]. GAPDH was used as an endogenous
control.
Transfection
Primary epithelial cell cultures at the fourth passage were
harvested, seeded at a density of 0.5610
5cells/well in a 6 well culture
plate coated with type-I collagen, and maintained in 2 ml of medium
until they reached 50–60% confluency. The epithelial cells were
transfected with 100 pmol of siGSK-3b or siSphk-1 or non-target
siRNA pool. Briefly, 100 pmol of siRNA was mixed with siPORT
NeoFX Transfection Agent and incubated at room temperature for
15 min. The transfection mixture was then added drop wise to the
respective wells and the reaction was incubated overnight. The
following morning, the medium was replaced and cells were
challenged as mentioned above. For pcDNA3-GSK3-b (S9A),
pcDNA3-GSK3-b (K85A), pcDNA3 (empty vector control) and
Sphk-1 overexpression, the plasmids were mixed with Fugene 6
transfection reagent and incubated for 15 min. The mixture was then
added dropwise to the cells and transfection reaction was carried out
for 24 h after which the cells were challenged as detailed above.
Western blotting
The Westernblotswereperformed byloading 50 mgto ta lpr o te in s
on to each lane [26]. After electrophoresis, the membranes were
incubatedwithantibodyagainstphospho- Sphk-1(Ser225)antibody,
phospho-ERK p42/p44 antibody, phospho-Glycogen synthase
(Ser641) and b-actin used as loading control. The membranes were
developed using ECL plus
TM western blotting detection reagent (GE
Healthcare, Piscataway, NJ) and exposed using KODAK Imaging
station 4000 MM with chemiluminescence detection. Brightness
and contrast if needed were adjusted using powerpoint.
Statistical analysis
The mRNA fold increase data was calculated according DDCT
method of Livak et al. [27]. Statistical analysis (analysis of variance
and Tukey multiple comparison test) was done using GraphPad
Pism 5.0 and GraphPad Instat 3.0. Statistical differences were
considered significant at the p,0.05 level and indicated by an
asterisk p,0.05 (*).
Results
Dose dependent inhibition of HBD-2 by Sphk-1 inhibition
Sphk-1 catalyzes a novel lipid messenger S1P [13]. S1P
regulates diverse physiological and pathological processes includ-
ing cancer and inflammation involving proliferation, migration,
invasion, and angiogenesis in vitro and in animals [14,28,29].
HBD-2 is upregulated in various cancers [30,31,32,33]. Based on
these findings, we hypothesized that a direct link between the
upregulation of Sphk-1, S1P and the induction of HBD-2 in oral
keratinocytes. To address our hypothesis, we utilized the TLR2
ligand (FSL-1) to challenge HGECs as TLR2 has been shown to
be an important receptor in gingival epithelial cell innate immune
responses [26,34]. First we pretreated primary HGECs with
various concentrations of Sphk-1 inhibitor for 2 h followed by
stimulating the cells with FSL-1 to determine the optimal dose.
After 24 h of challenge, we measured HBD-2 induction by ELISA.
The inhibition of Sphk-1 by a pharmacological inhibitor dose
dependently inhibited the induction of HBD-2 in HGECs
(Fig. 1A). We also wanted to check the phosphorylation state of
Sphk-1 in the presence of Sphk-1 inhibitor to verify its kinase
activity because the phosphorylation of Sphk-1 at Ser225 has been
shown to elevate its kinase activity by increasing S1P production
[20]. The total protein from the 60 min challenge with FSL-1 in
the presence of different concentration of Sphk-1 inhibitor was
subjected to immunoblot against phospho-specific Sphk-1
(Ser225). The inhibition revealed a dose dependent decrease in
the level of phosphorylation of Sphk-1 at serine 225 (Fig. 1B). The
phosphorylation of Sphk-1 at serine 225 by ERK 1/2 is critical for
the activation of NF-kB by S1P [20]. Hence a decrease in the
phophorylation level of Sphk-1 may account for decreased NF-kB
activity limiting HBD-2 mRNA transcriptional activation: as NF-
kB has been shown to be a critical transcription factor in the
induction of HBD-2 [35].
Inhibition of Sphk-1 abrogates HBD2 induction by
keratinocytes
HBD-2 can be induced by the activation of various TLRs and
possess strong antibacterial activity against Gram-negative bacte-
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finding, we challenged HGECs with various TLR ligands either in
the presence or absence of Sphk1 inhibiton for TLR2 (heat killed
P. gingivalis, P. gingivalis LPS, Pam3CSK4, FSL-1) TLR3 (Poly I:C),
TLR4 (E. coli LPS), TLR5 (Flagellin), TLR7 (ssRNA &
Imiquimod), TLR9 (ODN) after determining the optimal doses
for each of the agonists. Surprisingly, HBD-2 induction was
significantly down-regulated in the presence of Sphk-1 inhibitor in
cells treated with TLR ligands (Fig. 2A). This inhibition
demonstrates that Sphk-1 activation is crucial in TLR mediated
induction of HBD-2. It has already been shown that HBD-2 can
be strongly induced by exogenous TNFa and IL-1b cytokines [35].
To address this issue and to check the effect of Sphk-1 inhibition
on TNF and IL-1 receptors, we challenged the cells with IL-1a,
IL-1b and TNFa in the presence or absence of Sphk-1 inhibition.
We also utilized S1P, a ligand for the S1P1 receptor [19] in the
presence or absence of the Sphk-1 inhibitor (sphingosine is
converted to S1P by sphingosine kinase) [29]. Sphk-1 inhibitor
strongly inhibited the induction of HBD-2 in cells treated with
cytokines but not with the addition of extracellular S1P (Fig. 2B &
C). Next, we performed a time course experiment for determining
the phosphorylation state of Sphk-1 in the presence of inhibitor.
The phosphorylation of Sphk-1 at Ser225 started as early as
30 min and reached its maximum at 90 min after addition of FSL-
1 to the cells. However, the pharmacological inhibition of Sphk-1
down regulated its kinase activity by down regulating phosphor-
ylation on Ser225 (Fig. 2D). We wanted to examine whether
silencing of Sphk-1 mRNA with siRNA against Sphk-1 has the
same effect as the pharmacological inhibition. HBD-2 induction
was measured in HGECs transfected either with siRNA against
Sphk-1 or non targeting siRNA, 24 h after challenge with FSL-1,
Imiquimod and IL-1b. RNA silencing also revealed significant
down regulation of HBD-2 in the cells transfected with siRNA
against Sphk-1 confirming the results from pharmacological
inhibition (Fig. 3A). We noted that the exogenous addition of
S1P to the cells failed to induce HBD-2, in contrast to the data
obtained in a mouse model [23], so we were compelled to examine
the intracellular S1P levels both in the challenged state and also
with inhibitor. Indeed, the agonist FSL-1 induced significantly
higher intracellular S1P, an increase which was abrogated in the
presence of Sphk-1 inhibitor (Fig. 3B) and correlated with the
phosphorylation state of Sphk-1. Further, we wanted to test if
Sphk-2 contributed to the increase of intracellular S1P levels in
HGECs after challenging with FSL-1. Thus we performed real
time PCR to determine the mRNA expression levels of both Sphk-
1 and Sphk-2 in the challenged state. Sphk-1 mRNA expression
was significantly upregulated compared to Sphk2 upon FSL-1
challenge (Fig. 3C). This data demonstrates that Sphk-1 is the
predominant sphingosine kinase involved in the intracellular
conversion of S1P in HGECs. These results clearly show
intracellular S1P plays an important role in the induction of
HBD-2 and also underline the importance of phosphorylated
Sphk-1 at Ser225 in converting S1P when TLRs are triggered.
GSK-3b inhibition augments HBD-2 in oral keratinocytes
GSK3b is one of the major kinases involved in TLR signaling
and is a serine threonine kinase regulating various cellular
processes [39,40]. GSK3 can be inhibited by phospho-Akt, a
member of the PI3K pathway [41]. Its inhibition by lithium or SB
216763 (pharmacological inhibitor) increased the anti-inflamma-
tory cytokine IL-10 by driving the cells from the inflammatory
pathway towards an anti-inflammatory pathway [41]. In A549
cells, PI3K has been shown to regulate HBD-2 secretion [35] and
recently an antimicrobial peptide LL-37 has been shown to be
upregulated by increased PI3K activity and the Akt pathway,
suppressing GSK3 phosphorylation in HaCat cell lines [42].
Moreover, HBD-2 has also been shown to have anti-inflammatory
properties like IL-10 [43]. Since GSK-3b is regulated by PI3K
[41], we wanted to test whether the inhibitors against PI3K, AKT,
MEK 1/2 and GSK3 influence HBD-2 induction in HGECs. We
first pretreated HGECs with LY 294002 and Wortmannin (PI3K
inhibitors), AKT inhibitor, U0126 (MEK inhibitor) and SB-
216763 (GSK3 inhibitor) for 2 h followed by FSL-1 treatment for
24 h prior to measuring HBD-2 induction. The inhibitors of
PI3K, AKT and U0126 abrogated the secretion of HBD-2
whereas GSK3 inhibitor induced significantly higher amounts of
HBD-2 compared to FSL-1 alone. This data demonstrated that
inhibition of GSK3 by SB 216763 augmented HBD-2 secretion
via the PI3K dependent pathway (Fig. 4A). Our data on PI3K
activity is in agreement with the HBD-2 induction reported in
A549 cells [35]. We also wanted to test whether Sphk-1 is up or
downstream of PI3K. If Sphk-1 is downstream of PI3K, the
pharmacological inhibition of PI3K should down regulate Sphk-1
activity. To demonstrate this, the cells were pretreated with PI3K
inhibitor LY294002 for 2 h and challenged with FSL-1 for 0, 30,
60, 90, 120 and 240 min. The total protein was collected and
subjected to immunoblot against Sphk-1 phospho-specific anti-
body (Ser225). The immunoblot data clearly shows PI3K
Figure 1. Dose dependent inhibition of HBD-2 induction in
HGECs upon Sphk-1 inhibition. Keratinocytes were pretreated with
Sphk-1 inhibitor at various concentrations ranging from 0.1 mMt o
5.0 mM for 2 h prior to challenging the cells with FSL-1 ligand (1 mg/ml)
for 24. Supernatant was subjected to human HBD-2 ELISA. Sphk-1
inhibitor dose dependently inhibited the induction of HBD-2 (A). In
another set of experiment, total protein was collected after 60 min of
challenge as mentioned above. Immunoblot was performed with
ser225 phospho specific Sphk-1 antibody and b-actin as loading
control. The level of phosphorylation of Sphk-1 at ser225 was dose
dependently down regulated upon Sphk-1 inhibitor treatment (B).
Results are mean 6 SEM and are representative of three independent
experiments.
doi:10.1371/journal.pone.0011512.g001
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phosphorylation of Sphk-1 at Ser225 (Fig. 4B) and confirms that
the Sphk-1 is downstream of PI3K in HGECs.
The findings from the pharmacological inhibition of GSK3
compelled us to confirm if RNA silencing of GSK3-b will have
similar effect to that of the inhibitor SB 216763. To address this,
we transfected HGECs with siRNA against GSK3-b and
challenged the cells with FSL-1 for 24 h. The silencing of GSK-
3b significantly increased the induction of HBD-2 in the presence
of FSL-1 demonstrating that the inhibition of GSK3-b either by
siRNA or by pharmacological inhibition can augment HBD-2
induction in HGECs (Fig. 4C). Interestingly, we could not detect
IL-10 in the culture supernatants of HGECs even after 96 h of
post challenge with E. coli LPS, FSL-1, PAM3CSK4, Poly I:C or
with heat inactivated P. gingivalis in the presence or absence of
GSK3 inhibition.
The involvement of GSK-3b in regulating ERK 1/2 activation
was assessed by pretreating the cells with U0126 and/or
SB216763 before challenging with FSL-1 for 24 h. HBD-2
induction was dramatically upregulated in the presence of
SB216763 and FSL-1. This upregulation was ablated in the
presence of U0126 and SB216763 together (Fig. 4D). This data is
in agreement with Rehani et al. (2008) who show that ERK 1/2
activation is mediated by the inhibition of GSK-3b [44]. We
Figure 3. RNAi mediated inhibition of Sphk-1 inhibits agonists induced HBD-2. The cells were transiently transfected with siRNA against
Sphk-1 and incubated with FSL-1 (1 mg/ml), Imiquimod (0.1 mg/ml) and IL-1b (2.5 ng/ml). The supernatant was collected after 24 h challenge and
subjected to human HBD-2 ELISA. siRNA against Sphk-1 down modulated agonist induced HBD-2 in HGECs (A). Intracellular S1P was measured using
S1P ELISA kit after challenging with FSL-1 (1 mg/ml) for 2 h in cells pre-incubated with Sphk-1 inhibitor. The reaction was terminated after 2 h and
100 mg of total protein was subjected to ELISA. The intracellular S1P production was downregulated by Sphk-1 inhibitor (B). Total RNA was collected
and converted to cDNA from the cells challenged with FSL-1 (1 mg/ml) for 24 h. cDNA was subjected to real time PCR with Sphk-1, Sphk-2 and
GAPDH endogenous control TaqMan probes. Sphk-1 mRNA expression was highly upregulated compared to Sphk2 mRNA expression showing Sphk-
1 as a predominant kinase in HGECs upon ligand challenge (C). Control cells received DMSO unless otherwise stated. Results are mean 6 SEM and are
representative of three independent experiments. Statistical comparisons are shown by horizontal bars with asterisks above them (* indicates p,0.05
determined by ANOVA and Tukey multiple comparison test).
doi:10.1371/journal.pone.0011512.g003
Figure 2. Sphk-1 inhibition down modulates agonists induced HBD-2. Oral keratinocytes were incubated with or without Sphk-1 inhibitor
(2 mM) for 2 h prior to challenging the cells with various TLR agonists namely, heat inactivated P. gingivalis (MOI:100), FSL-1 (1 mg/ml), Pam3CSK4
(0.5 mg/ml), P.gingivalis LPS (1 mg/ml), E. Coli LPS (1 mg/ml), ssRNA (0.1 mg/ml), Poly I:C (5 mg/ml) ODN (0.5 mg/ml), Imiquimod (0.1 mg/ml), Flagellin
(0.25 mg/mL) (A); the IL-1a (2.5 ng/ml), IL-1b (2.5 ng/ml) and TNF-a (2.5 ng/ml) (B) and GPCR agonist S1P (100 nM) (C) for 24 h. The supernatant was
collected after 24 h and HBD-2 ELISA was performed using Human BD-2 ELISA kit. The Sphk-1 inhibitor ablated HBD-2 induction with the agonists
tested. The time course experiment was performed by pretreating the cells with Sphk-1 (2 mg/ml) for 2 h before challenging with FSL-1 (1 mg/ml) for
0, 30, 60, 90, 120 and 240 min. The total protein was collected and subjected to immunoblot with ser225 phospho specific Sphk-1 antibody and b-
actin as loading control. We noted increase in the phosphorylation level of Sphk-1 at ser225 as early as 60 min and the level of phosphorylation was
down regulated in the presence of Sphk-1 inhibitor (D). Control cells received DMSO unless otherwise stated. Results are mean 6 SEM and are
representative of three independent experiments. Statistical comparisons are shown by horizontal bars with asterisks above them (* indicates p,0.05
determined by ANOVA and Tukey multiple comparison test).
doi:10.1371/journal.pone.0011512.g002
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–0.5 mM) or Akt inhibitor (10 mM) or MEK 1/2, U0126 (25 uM) or GSK3 inhibitor (SB216763-12 mM) 2 h before challenging with FSL-1(1 mg/ml) for 24 h.
The supernatant was subjected to human HBD-2 ELISA. PI3K, Akt and MEK inhibitors abrogated HBD-2 induction whereas GSK3 inhibitor augmented
HBD-2 induction in HGECs (A). The cells were pretreated with LY294002 (10 mM) for 2 h and challenged with FSL-1 (1 mg/ml) for 0, 30, 60, 90, 120 and
240 min. Total protein was subjected to immunoblot against phospho- ser225 Sphk-1 antibody with b-actin as loading control. PI3K inhibitor
downregulated the phosphorylation level of Sphk-1 at Ser225 demonstrating the pivotal role of PI3K in Sphk-1 activation (B). The cells were transient
transfected of siRNA against GSK-3b and challenged with FSL-1 (1 mg/ml) for 24 h and supernatants were subjected to human HBD-2 ELISA. siGSK3-b
up regulated HBD-2 induction after challenging with FSL-1. This upregulation of HBD-2 was significantly higher to FSL-1 challenge alone (C). The cells
were either pretreated with U0126 (25 uM) and/or SB216763 (12 mM) prior to challenging with FSL-1 (1 mg/ml) for 24 h and supernatant was
subjected to HBD-2 ELISA. GSK3 inhibitor augmented the HBD-2 induction whereas the cells with GSK3 +MEK 1/2 inhibitor ablated HBD-2 induction
(D). Phospho-Glycogen synthase (Ser641) levels were assessed by incubating SB216763 (12 mM) for 2 h prior to challenge with FSL-1 for 0, 30 and
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thus Glycogen synthase activity. To address this, the cells were
pretreated with SB216763 and challenged with FSL-1 for 0, 30
and 60 min. The activity of Glycogen synthase was assessed by
immunoblotting against phospho-Glycogen synthase (Ser641)
antibody. The phosphorylation level of Glycogen synthase at
Ser641 was significantly down regulated in the presence of
SB216763 and FSL-1 demonstrating the specificity of GSK3
inhibition (Fig. 4E). Interestingly, the phophorylation levels of
Sphk-1 at ser225 and ERK p42/p44 increased upon GSK3
inhibition (Fig. 4F). The increase in Sphk-1 might be due to the
increase in ERK phosphorylation and its ability to phosphorylate
Sphk-1 at Ser225 as observed earlier [20]. We also tested if Sphk-1
inhibition had any effect on ERK 1/2 activity. The inhibition of
Sphk-1 showed no significant effect on ERK 1/2 activity as
revealed by its phosphorylation at 60 min post challenge with
Sphk-1 inhibition (Fig. 4G). This data demonstrates that Sphk-1 is
a downstream kinase to ERK 1/2 in HGECs.
GSK3-b over-expression downregulated HBD-2 induction
Since we noted dramatic upregulation of HBD-2 following
inhibition of GSK3 by a potent selective inhibitor SB 216763 and
also by siRNA, we tested if the overexpression of GSK3-b
downregulates HBD-2. Thus HGECs were transfected with
plasmids carrying GSK3-b (K85A) expressing ‘kinase dead’ [45]
(that lack kinase activity) and GSK3-b (S9A) mutated plasmid to
see the effect on constitutively active GSK3-b and the contribution
of serine 9 phosphorylation to the induction of HBD-2. After 24 h
of transfection, the cells were challenged with FSL-1 for 24 h and
HBD-2 levels were measured in the supernatants. When we over-
expressed the constitutively active GSK3-b (S9A) followed by FSL-
1 stimulation, the induction of HBD-2 was attenuated. However,
when kinase dead GSK3-b (K85) was over-expressed, the HBD-2
induction was dramatically increased following FSL-1 challenge
demonstrating GSK3-b strongly modulates HBD-2 induction in
HGECs (Fig. 5A).
Over-expression of Sphk-1 enhances HBD-2 induction
Sphk-1 has been shown to possess anti-apoptotic activity [46], in
part due to increased intracellular S1P levels, because S1P
regulates cellular proliferation [15]. Interestingly, HBD-2 levels
have been shown to be higher in proliferating cells [47]. Since we
noted the abrogation of HBD-2 by Sphk-1 inhibitor, we wanted to
overexpress Sphk-1 in HGECs to check if it contributes to increase
in the induction HBD-2. To demonstrate this, we over-expressed
the Sphk-1 in HGECs by transient transfection. After 24 h of
transfection, the cells were cultured with FSL-1 - for 24 h. The
overexpression of Sphk-1 in HGECs markedly increased HBD-2
levels after FSL-1 challenge (Fig. 5B) confirming our hypothesis.
Further, we also wanted to see the effect of HBD-2 induction by
concomitant inhibition of GSK3 in cells overexpressing Sphk-1.
First, we transfected the cells with Sphk-1 plasmid and at 24 h post
transfection we pretreated the cells with SB 216763 for 2 h
followed by FSL-1 treatment for 24 h. After 24 h of challenge, we
noted robust increases in the induction of HBD-2 upon GSK3
inhibition in cells over-expressing Sphk-1. This data clearly
demonstrates the pivotal roles of Sphk-1 and GSK3-b in the
induction of HBD-2 (Fig. 5B).
We further investigated NF-kB activity by measuring p65 in
cells pretreated with Sphk-1 inhibitor to check whether Sphk-1
inhibition caused NF-kB inactivation leading to down-regulated
HBD-2 induction. The Sphk-1 inhibitor reduced NF-kB activity in
HGECs upon FSL-1 treatment (but did not result in complete
inhibition at the 2 mM concentration). This result is in agreement
with the previously observed NF-kB activation following blocking
of Sphk1 by anti-sense oligo [48]. Intriguingly, the inhibition of
GSK3 by SB 216763 strongly upregulated NF-kB activity (Fig. 5C).
The upregulation of NF-kB in the inhibition of GSK3 by SB
216763 shows that the kinase activity of GSK3 functions
differently in non-myeloid cells and does not modulate IL-10
expression as it does in immune cells [41]. However, the
mechanism of this increase in NF-kB activity upon inhibition of
GSK3 in epithelial cells has yet to be explored. Since we noted
upregulation of both ERK 1/2 and NF-kB on GSK-3 inhibition in
HGECs, we wanted to see if there was any difference in
proinflammatory cytokine induction. Interestingly, the induction
of proinflammatory cytokines (IL-6, TNFa and IL-1b) was
significantly upregulated upon GSK3 inhibition by SB 216763
(Fig. 5D). This is in marked contrast to immune cells where GSK3
inhibition down regulated proinflammatory cytokines [41].
Further investigation of the transcription factor CREB and its
interaction with CBP in HGECs might uncover the mechanism
for the different effects of GSK3 in non-myeloid cells.
Discussion
Microbial elimination is a critical step in controlling the onset of
chronic inflammation. Although this can be achieved by antibiotic
treatment, development of microbial resistance is increasingly
limiting antibiotic utility [49]. For this reason, a number of small
molecules have been identified that may function as antimicrobial
agents [50]. Short cationic peptides produced by cells with
antibacterial and/or immunomodulatory activity are being
heralded as novel approaches in the control of bacterial
pathogenesis [51]. HBD-2 is an antimicrobial peptide that can
be strongly induced by various microbial products. Stimulation of
TLRs by its ligands results in the recruitment of an adaptor
molecule, Myd88, which activates a downstream signaling
pathway that includes interleukin 1 receptor associated kinase
(IRAK) [52], which in turn activates NF-kB, p38 and JNK
pathways that lead to proinflammatory cytokine and antimicrobial
peptide secretion. Other than antimicrobial activity, HBD-2 has
been shown to possess chemotactic properties, induce cytokines,
promote DC maturation and antigen-specific B and T cell
responses [53]. HBD-2 is primarily potent against Gram-negative
bacteria [53] and disrupts bacterial membranes by electrostatic
interaction between the HBD-2 and the negatively charged
phospholipids on the bacteria or by formation of ion channels
60 min. Total protein was subjected to immunoblot against Phospho-Glycogen synthase (Ser641) antibody with b-actin as loading control. The
phosphorylation of Glycogen synthase at Ser641 was down regulated in the presence of SB216763 (E). Time course experiment was performed either
in the presence or absence of SB 216763 inhibitor (GSK3) (12 mM). The cells were challenged with FSL-1 (1 mg/ml) and the total protein was collected
at 15, 30 and 60 min and subjected to immunoblot against phospho- ser225 Sphk-1 antibody and p44/42 MAPK (Erk1/2) antibody with b-actin as
loading control. Inhibition of GSK3 by SB 216763 increased the Sphk-1 phospho-ser225 at 60 min, ERK 1/2 phosphorylation increased at 30 min of
agonist challenge (F). The phosphorylation of p44/42 MAPK (Erk1/2) was unaltered upon Sphk-1 inhibitor after 60 min demonstrating Sphk-1
downstream of Erk 1/2 (G). Control cells received DMSO unless otherwise stated. Results are mean 6 SEM and are representative of three
independent experiments. Statistical comparisons are shown by horizontal bars with asterisks above them (* indicates p,0.05 determined by ANOVA
and Tukey multiple comparison test).
doi:10.1371/journal.pone.0011512.g004
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PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11512Figure 5. Overexpression of GSK3-b in HGECs. Cells were transiently transfected with GSK3-b (S9A), GSK3-b (K85) and pCDNA3.1 as Mock using
Fugene 6. The transfected cells were challenged with FSL-1 (1 mg/ml) for 24 h. The supernatant was subjected to human HBD-2 ELISA. The cells
transfected with kinase dead GSK-3b (K85) plasmid induced significantly higher amounts of HBD-2 however; the cells transfected with constitutively
active GSK3-b (S9A) attenuated HBD-2 induction (A). We overexpressed Sphk-1 by transfecting the cells with Sphk-1 plasmid and incubated in the
presence or absence of GSK3-b inhibitor SB 216763. The FSL-1 (1 mg/ml) challenged cells induced significantly higher amounts of HBD-2 compared to
the cells without GSK3 inhibition (B). NF-kB p65 activity was measured in the presence or absence of Sphk-1 and GSK3 inhibitor. Sphk-1 inhibition
reduced NF-kb activity however, NF-kb activity increased upon GSK3 inhibition when challenged with FSL-1 (1 mg/ml) (C). The cells were pretreated
with SB216763 for 2 h prior to challenging with FSL-1 for 24 h and supernatant was subjected to ELISA using appropriate kits. IL-1b, TNFa and IL-6
were significantly upregulated upon GSK3 inhibition in the presence of FSL-1 (D). Control cells received DMSO unless otherwise stated. Results are
mean 6 SEM of triplicates and are representative of three independent experiments. Statistical comparisons are shown by horizontal bars with
asterisks above them (* indicates p,0.05 determined by ANOVA and Tukey multiple comparison test).
doi:10.1371/journal.pone.0011512.g005
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host cells and inhibiting pathogen replication [53,54,55,56]. There
are several reports on the regulation and secretion of HBD-2 in
various types of cells [57,58,59,60,61,62]. However, the mecha-
nism of HBD-2 induction by various microbial products that elicit
antimicrobial defense through TLRs in epithelial cells has not
been elucidated. Epithelial cell signaling is crucial in early defense
against microbes as is HBD-2 regulation and secretion, in the
recognition and clearance of bacteria in chronic inflammatory
diseases such as periodontitis. Enhancing the production of
epithelial HBD-2 to combat the pathogen attack is a valuable
approach against sepsis.
It has recently been shown that the gene specific chromatin
remodeling, accounts for transient silencing of proinflammatory
cytokine genes and promoting antimicrobial gene activation [63].
Here we report for the first time the involvement of a novel kinase,
Sphk-1 in the induction of the antimicrobial peptide HBD-2 that is
augmented by suppressing GSK3-b in human oral keratinocytes
independent of proinflammatory cytokine induction that involve
TLRs-PI3K-Akt-GSK3-ERK1/2-Sphk-1 (Fig. 6). Moreover, we
also show that the activation of various TLRs and cytokines such
as IL-1a/b and TNFa can induce HBD-2, and Sphk-1 inhibition
can ablate this induction. S1P has been shown to induce
antimicrobial activity in a mouse model of Mycobacterium tuberculosis
infection, both in vivo and in vitro [21,22,23]. The host’s innate
immune response to M. tuberculosis is mainly elicited by TLR2 [64].
However, the mechanism of antimicrobial activity in these cases
has not been explored. We have previously shown that S1P in
combination with LPS cooperate in the induction of proinflam-
matory cytokines and the inhibition of Sphk-1 did not affect the
induction of proinflammatory cytokines in HGECs [65]. Here we
demonstrate that the Sphk-1 inhibitor dose dependently down-
regulated HBD-2 induction through all the TLR ligands and
cytokines tested. Additionally, we show that Sphk-1 is predomi-
nantly activated compared to its isoform Sphk-2 by a TLR2 ligand
in HGECs. In order to confirm and extend the mechanism behind
this, we carried out experiments using TLR2 as a representative
receptor because TLR2 has been implicated as an important
receptor in the human gingival keratinocyte innate immune
response [26] and is required for innate responses to P. gingivalis
[66] and its clearance in vivo [67] and also has been shown to
activate PI3K [68]. It is well known that PI3K can mediate
activation of various TLRs [69] hence it is plausible to focus on
TLR2 as a model receptor to dissect HBD-2 induction pathway by
TLRs in HGECs. Interestingly, TLR2 stimulation enhanced
Sphk-1 activation by increasing its phosphorylation at Ser225.
Phosphorylation events of Sphk-1 are dependent on ERK 1/2
[20]. The only phosphorylation site of Sphk-1 at Ser225 is
involved not only in its catalytic activity but is also important in its
translocation to the plasma membrane [29] where sphingosine is
converted to S1P and this conversion leads to cell proliferation and
survival which is supported by over-expression of kinase inactive
enzyme [70]. In conjunction, HBD-2 has been shown to be
elevated in proliferating cells [47]. Our data on phosphorylation of
Sphk-1 is in agreement with the above wherein PI3K and MEK
inhibitor suppressed the agonist activated phosphorylation of
Sphk-1 as well as the induction of HBD-2. Moreover, Sphk-1
inhibition did not affect the activation of ERK 1/2 in HGECs.
Interestingly, HBD-2 activity is also increased in some viral
infections such as activity against RSV infection [71], viral
haemorrhagic septicaemia rhabdovirus [72], HIV-I [73], and
papilloma virus [74]. Moreover, the activity of Sphk-1 has been
shown to be increased in viral infections [75]. Compatible with the
above, inhibition of Sphk-1 has been shown to increase NS3 viral
replication in bovine viral diarrhea [75]. Perhaps, the inhibition of
Sphk-1 may result in down regulation of antimicrobial peptide
synthesis which might have affected enhanced viral replication.
Hence increasing HBD-2 by modulating the kinase activity of
Sphk-1 and kinase inactivation of GSK3-b can be seen as a
valuable intervention against viral attack.
GSK3 is part of the PI3K signaling network and is also one of
the major kinases regulating TLR signaling. Inhibition of GSK3
by lithium or SB 216763 (pharmacological inhibitor) or by siRNA
increased the anti-inflammatory cytokine IL-10 by driving the
immune cells from an inflammatory to an anti-inflammatory
pathway [41]. S1P has also been reported to induce anti-
inflammatory activity, which is achieved by sequestering lympho-
cytes in lymph nodes [76]. To our surprise, the inhibition of
GSK3-b augmented both HBD-2 and proinflammatory cytokines
like IL-6, TNFa and IL-1b. In support of this, transient silencing
of GSK3b up-regulated agonist induced HBD-2. Further, the
agonist induced HBD-2 was down-regulated by ERK 1/2
inhibition. In addition inhibition of both GSK3 and ERK 1/2
at the same time down-regulated HBD-2. This indicates that the
inhibition of GSK3 enhances ERK 1/2 activation. To further
verify whether and if GSK3 inhibition is specific, the phosphor-
ylation of glycogen-synthase kinase (a downstream kinase of
GSK3) was assessed. The phosphorylation level of glycogen-
synthase (Ser641) was markedly down regulated with SB 216763
treatment demonstrating the efficacy of GSK3 inhibition. The
inhibitory role of GSK3-b was further verified by over-expression
of kinase dead GSK3-b. In this case constitutively active GSK3b
(S9A) inhibited HBD-2 possibly blocking the activation of ERK 1/
2. But the secretion of HBD-2 was restored by kinase dead GSK3-
b over-expression. Concomitant overexpression and suppression of
Sphk-1 and GSK3 respectively, yielded higher HBD-2 induction.
Our present findings demonstrate that Sphk-1 regulates HBD-2
induction by TLRs at least in human oral epithelial cells. The
suppression of HBD-2 by pharmacological inhibition of Sphk-1
was further confirmed with RNAi. We have also experimentally
shown the increase in Sphk-1 activity by TLR activation
contributes to an increase in the intracellular S1P. In contrast to
intracellular S1P data, extracellular addition of S1P failed to up-
regulate HBD-2 in our model. Activation of S1P1 by extracellular
S1P may require TLR cooperation as demonstrated earlier [65].
However, further experimental evidence is needed to confirm the
role of extracellular activation of S1P1 in gingival keratinocytes.
The increase in Sphk-1 activity may be due to the up regulated
ERK 1/2 phosphorylation and agonist induced GSK3-b inhibi-
tion. Additionally, PI3K involvement in increasing ERK 1/2
phosphorylation by inhibition of GSK3 has been shown previously
[77,78]. This increase might be due to the suppression of phospho-
RAC1 at Ser71 and subsequent phosphorylation of PAK1 at
Ser199/204 and cRaf at Ser338 activating ERK 1/2 as observed
in human monocytes by Rehani et al. (2008) [44] or due to the
activation of PKCd as observed in human cell lines HT29 and
Caco-2 by Wang et al. (2006) [79]. In contrast to the above
findings, we observed increased NF-kB activity upon GSK3
inhibition. This show GSK3 negatively or positively affects either
ERK 1/2 and/or NF-kB in a cell type specific manner. Further
understanding of the involvement of different transcription factors
will answer basic mechanistic questions involved in HBD-2
induction. In HGECs, ligand induced suppression of GSK3-b
may induce chromatin modifications of both proinflammatory
cytokine and antimicrobial peptide genes that result in higher gene
activation. Activation of proinflammatory genes after GSK3
inhibition may be exclusive to non-myeloid cells such as HGECs
as similar experiments with immune cells show decreased
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IL-10 calls into question the ability of epithelial cells to dampen
the inflammation caused by bacteria or viruses. Epithelium may
have been evolved to induce proinflammatory cytokines and
chemokines to recruit immune cells to the site of infection in lieu of
secreting anti-inflammatory cytokine such as IL-10 to dampen the
Figure 6. Model of mechanism involved in HBD-2 secretion in gingival epithelial cells. Triggering TLRs by respective ligand stimulates the
cells to induce HBD-2. This induction can be ablated by a pharmacological inhibitor against Sphk-1, and inhibition of GSK3 by SB216763 or siGSK3-b
in the absence of Sphk-1 inhibition can augment HBD-2 secretion. Inhibition of PI3K by either wortmannin or LY294002 abrogated HBD-2 in gingival
epithelial cells. PI3K activated Akt, the phosphorylation of Akt inhibited GSK3 in turn activating ERK 1/2. ERK 1/2 activates Sphk-1 by phosphorylation
at Ser225 and increase NF-kB activity. This show PI3K-Akt-GSK3-ERK1/2-Sphk-1 mediates HBD-2 synthesis in gingival epithelial cells.
doi:10.1371/journal.pone.0011512.g006
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peptides to combat against invading microbes.
The present investigation identifies: i) Sphk-1 as a critical kinase
involved in TLR mediated human b-defensin 2 induction and
modulation in HGECs; ii) activation of TLRs induces phosphor-
ylation of Sphk-1 and its intracellular activity by enhanced
conversion of S1P; and iii) activated PI3K suppresses GSK3-b
augmenting HBD-2 induction. Collectively, it is plausible to
hypothesize that the modulation of Sphk-1 and GSK3-b to induce
and enhance HBD-2 production may help cells combat bacterial
insult and thus they have potential therapeutic value.
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